
News|Articles|July 1, 2003
Doxorubicin-related CHF more frequent than previously reported
The utility of doxorubicin is limited by the risk of cumulative, dose-related, progressive myocardial damage.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Growth of GLP-1 therapies has reshaped the market | PBMI 2026
2
Judi Health, Employers Health team up to launch new PBM solution
3
Amy Wadstrom, RPh, on mid-size PBMs and leaving the ‘big three’ | PBMI 2026
4
Amivantamab, chemo combo shows nearly 3-year survival in EGFR exon 20 lung cancer
5
























